Skip to main content

Table 4 Multivariate Cox regression analyses of the overall survival and disease-free survival according to the level of γ-GT before and after PSM

From: Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization

Characteristics OS    DFS
Before PSM After PSM Before PSM After PSM
HR (95CI) P-value HR (95CI) P-value HR (95CI) P-value HR (95CI) P-value
γ-GT ≤ 54 U/L
 Tumor number (Multiple vs Single) 2.11 (1.55–2.87) < 0.001 1.97 (1.33–2.93) 0.001 2.07 (1.61–2.65) < 0.001 2.18 (1.59–2.98) < 0.001
 Tumor diameter (cm) 1.11 (1.07–1.15) < 0.001 1.11 (1.05–1.17) < 0.001 1.08 (1.04–1.12) < 0.001 1.08 (1.03–1.13) 0.003
 Capsule (Absent vs Present) 1.36 (1.02–1.81) 0.039 1.41 (0.95–2.09) 0.085 – – – –
 MVI (Absent vs Present) 1.58 (1.22–2.06) 0.001 1.57 (1.10–2.26) 0.014 1.44 (1.16–1.79) 0.001 1.45 (1.08–1.95) 0.014
 PA-TACE (Yes vs No) 0.85 (0.65–1.11) 0.222 0.89 (0.64–1.23) 0.471 0.86 (0.69–1.08) 0.190 0.91 (0.71–1.18) 0.483
γ-GT > 54 U/L
 TBil (μmol/L) 1.01 (1.00–1.03) 0.036 1.02 (1.01–1.04) 0.009 1.01 (1.00–1.03) 0.028 1.03 (1.01–1.05) < 0.001
 AFP (> 400 vs 400 ng/mL) 1.71 (1.39–2.10) < 0.001 1.71 (1.32–2.22) < 0.001 1.43 (1.20–1.71) < 0.001 1.47 (1.18–1.84) 0.001
 Tumor number (Multiple vs Single) – – – – 1.25 (1.01–1.56) 0.042 1.08 (0.82–1.42) 0.589
 Tumor diameter (cm) 1.06 (1.04–1.09) < 0.001 1.07 (1.04–1.10) < 0.001 1.03 (1.01–1.05) 0.008 1.04 (1.01–1.06) 0.005
 Capsule (Absent vs Present) 1.33 (1.05–1.68) 0.019 1.43 (1.05–1.95) 0.024 – – – –
 MVI (Absent vs Present) 1.43 (1.14–1.79) 0.002 1.21 (0.89–1.64) 0.219 1.37 (1.13–1.65) 0.001 1.19 (0.92–1.54) 0.174
 PA-TACE (Yes vs No) 0.69 (0.55–0.86) 0.001 0.66 (0.52–0.85) 0.001 0.76 (0.63–0.91) 0.003 0.74 (0.60–0.92) 0.006
  1. Note: OS overall survival; DFS disease-free survival; HR hazard ratio; CI confidence interval; PSM propensity score matching; γ-GT gamma-glutamyl transferase; TBil total bilirubin; AFP alpha-fetoprotein; MVI microvascular invasion; PA-TACE postoperative adjuvant transarterial chemoembolization
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us